Zusammenfassung
Ein effektives Screening existiert beim Ovarialkarzinom nicht. Die Verdachtsdiagnose eines Ovarialkarzinoms macht eine operative Abklärung mit histologischer Diagnosesicherung durch Laparotomie oder Laparoskopie notwendig. Es existiert keine präoperative Untersuchungsmethode, die eine Operation ersetzen könnte. Die Operation des Ovarialkarzinoms beginnt mit einer genauen und systematischen Exploration des gesamten Abdomens, mit dem Ziel, die Tumorausbreitung zu erfassen und die Operabilität zu beurteilen (operatives Staging). Bei fortgeschrittenem Karzinom erfolgt eine maximale Tumorreduktion im Becken und Abdomen mit dem Ziel, keinen Resttumor zurückzulassen (= optimales „Debulking“, R0-Resektion). Patientinnen mit einem Ovarialkarzinom im Stadium FIGO Ic oder Ia/Ib und Grad 3 sollen eine platinhaltige Chemotherapie über 6 Zyklen erhalten. Ab dem Stadium II ist eine Chemotherapie mit Carboplatin und Paclitaxel Standard. Bevacizumab kann zusätzlich verabreicht werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Aghajanian C, Blank S, Goff B, Judson P, Teneriello M, Husain A, Sovak M et al (2012) Oceans: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045
Benedetti-Panici P, Maggioni A, Hacker N et al (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–566
Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483
Collaborative Group on Epidemiological studies of ovarian cancer (2015) Monopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842
DuBois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase III multicenter trials: by the Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe Ovar (AGO-Ovar) and the Groupe d´Investigateurs Nationaux pour les etudes des cancers de l’ovarie (GINECO). Cancer 115:1234–1244
DuBois A, Riegler E, De Gregorio N, Reuss A, Mahner S, Fotopoulou C et al (2013) Borderline tumors of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Eur J Cancer 49:1905–1914
DuBois A, Vergote I, Ferron GH, Reuss A, Meier W, Greggi S et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: The interim analysis of AGO DESKTOP III/ENGOT ov20. J Clin Oncol 35, 15 Suppl, Abstr 5501
Eeles R, Morden J, Gore M, Mansi J, Glees J, Wenczl M et al (2015) Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial. J Clin Oncol 33:4138–4144
Gershenson D, Bodurka D, Coleman R, Lu K, Malpica A, Sun C (2017) Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35:1103–1111
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C et al (2017) LION – Lymphadenectomy in ovarian neoplasms: A prospective randomized AGO study group led Gynecologic Cancer Intergroup trial. J Clin Oncol, 35, 15 Suppl, Abstr 5500
Hogdall E, Karlesn M, Christensen I, Lundvall L, Engelholm S, Nedergaard L et al (2012) Diagnostic value of HE4, CA 125, and the ROMA index in ovarian cancer patients from a tertiary center. Int J Gynecol Cancer 22(S1):S42
Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:1331–1338
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Kurzversion 2.0, AWMF Registrierungsnummer 032/035OL, http://leitlinienprogramm-onkologie.de/Ovarialkarzinom.61.0html (Stand 2017)
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382–1392
Maggioni A, Benedetti-Panici P, Dell’Anna T et al (2006) Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95:699–704
Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393
Mirza MR, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New Engl J Med 375:2154–2164
Morice P, Wicart-Poque F, Rey et al (2001) Results of conservative treatment in epithelial ovarian carcinoma. Cancer 92: 1412–2418
Pearce C, Templeman C, Rossing M, Lee A, Near A, Webb P et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394
Perren T, Swart AM, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496
Petru E, Lahousen M, Tamussino K et al (1994) Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 170:656–662
Petru E, Kurschel S, Walsberger K et al (2003) Can bowel endoscopy predict colorectal surgery in patients with an adnexal mass? Int J Gynecol Cancer 13:292–296
Pignata S, Scambia G, Savarese A et al (2010) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: Final analysis of the MITO-2 randomized multicenter trial. J Clin Oncol 28 (Suppl) 952s (Abstract No. LBA5033)
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323–3329
Rosenthal A, Fraser L, Philpot S, Manchanda R, Burnell M, Badman P et al (2017) Evidence of tstage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol 35:1411–1420
Rustin G, Van der Burg M, Griffin C et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet 376:1155–1163
Sassone M, Timor-Tritsch I, Artner A et al (1991) Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78:70–76
Schelling M, Braun M, Kuhn W et al (2000) Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77:78–86
Trimbos B, Timmers P, Pecorelli S et al (2010) Surgical staging and treatment of early ovarian cancer: Long-term analysis of a randomized trial. J Natl Cancer Inst 102:982–987
Vang R, Shih lM, Kurman J (2009) Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: 267–282
Vergote I, Brabanter J, Fyles A et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–182
Vergote I, Trope C, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer. New Engl J Med 363:943–953
Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, DuBois A, Petru E et al (2013) S3-guideline on diagnostics, therapy and follow-up of malignant ovarian tumours. Geburtsh Frauenheilk 73:874–889
Winter W, Maxwell L, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 26:83–89
Young R, Decker D, Wharton et al (1983) Staging laparotomy in early ovarian cancer. JAMA 250: 3072–3076
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Petru, E., Moinfar, F., Winter, R., Tamussino, K., Sehouli, J. (2019). Maligne epitheliale Tumoren des Ovars. In: Petru, E., Fink, D., Köchli, O., Loibl, S. (eds) Praxisbuch Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57430-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-57430-0_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57429-4
Online ISBN: 978-3-662-57430-0
eBook Packages: Medicine (German Language)